ARTICLE SUMMARY:
Placental tissue allograft start-up StimLabs gains market clearance for Corplex P, a particulate product well-suited for wounds with irregular geometry.
Before founding wound care start-up StimLabs in 2015, CEO John Daniel spent 30 years in the tissue transplant field, beginning in orthopedics with cadaveric bone and connective tissue transplant. In the mid-aughts, Daniel began working with birth tissue and allograft transplant and started his first company, Surgical Biologics. One of the early entrants into the birth tissue allograft space, Surgical Biologics sold to MiMedx in 2011, giving Daniel some time to stand back and watch the market. After that exit, Daniel recalls, despite more companies becoming involved in the space, not much innovation was occurring. “There was more competition around growing market share and less about actually creating technologies that offer different treatment paradigms,” he says. In response, Daniel started StimLabs, self-funding the start-up with the mission of driving innovation so clinicians will have more wound management options and make a greater impact on both chronic and acute wounds.
